Dalrymple's sign

From WikiMD's WELLNESSPEDIA

Dalrymple's sign is a medical term referring to the abnormal widening of the palpebral fissure, or the opening between the eyelids, often associated with Graves' disease. This sign is named after British physician, John Dalrymple, who first described it in the 19th century.

Overview[edit]

Dalrymple's sign is characterized by an abnormal widening of the palpebral fissure, which is the opening between the upper and lower eyelids. This condition is often associated with Graves' disease, an autoimmune disorder that results in the overproduction of thyroid hormones, or hyperthyroidism.

Symptoms[edit]

The primary symptom of Dalrymple's sign is the abnormal widening of the palpebral fissure. This can result in the white part of the eye, or the sclera, being visible above and below the iris when the eyes are in a normal position. Other symptoms may include exophthalmos, or bulging of the eyes, and lid lag, a delay in the movement of the eyelid when the eye moves downward.

Causes[edit]

The main cause of Dalrymple's sign is Graves' disease. This autoimmune disorder causes the body's immune system to attack the thyroid gland, leading to an overproduction of thyroid hormones. These hormones can cause a variety of symptoms, including the abnormal widening of the palpebral fissure seen in Dalrymple's sign.

Diagnosis[edit]

Diagnosis of Dalrymple's sign is typically made through a physical examination of the eyes. The doctor may also order blood tests to check for the presence of thyroid hormones and antibodies associated with Graves' disease.

Treatment[edit]

Treatment for Dalrymple's sign typically involves addressing the underlying cause, which is often Graves' disease. This may involve medication to reduce the production of thyroid hormones, radioactive iodine therapy, or surgery to remove part or all of the thyroid gland.

See also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.